Title: Race and ethnicity as risk factors for colonization and infection with key bacterial pathogens: a scoping review

Authors: Esther E. Avendano[1], Sarah Addison Blackmon[2], Nanguneri Nirmala[3], Courtney W. Chan[4], Rebecca A. Morin[5], Sweta Balaji[6], Lily McNulty[7*], Samson Alemu Argaw[7], Shira Doron[8,9], Maya L. Nadimpalli[9,10#]

Affiliations:

[1]Avendano Consulting, Boston, MA, USA

[2]Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

[3]Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

[4]University of Massachusetts T.H. Chan School of Medicine, Worcester, MA, USA

[5]Hirsh Health Sciences Library, Tufts University, Boston, MA, USA

[6]Department of Quantitative Theory and Methods, Emory University, Atlanta, GA

[7]Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA

[8]Division of Geographic Medicine and Infectious Disease, Department of Medicine, Tufts Medical Center, Boston, MA, USA

[9]Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance (Levy CIMAR), Tufts University, Boston, MA, USA

[10]Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA

*Current affiliation: NORC at the University of Chicago, Washington, D.C.

#Address: Claudia Nance Rollins 6009, 1518 Clifton Rd NE, Atlanta GA 30322. Email: maya.l.nadimpalli@emory.edu.

ABSTRACT

Background: Racial and ethnic disparities in infectious disease burden have been reported in the USA and globally, most recently for COVID-19. It remains unclear whether such disparities also exist for priority bacterial pathogens that are increasingly antibiotic-resistant. We conducted a scoping review to summarize published studies that report on colonization or community-acquired infection with pathogens among different races and ethnicities.

Methods: We conducted an electronic literature search of MEDLINE®, Daily, Global Health, Embase, Cochrane Central, and Web of Science from inception to January 2022 for eligible observational studies. Abstracts and full-text publications were screened in duplicate for studies that reported data for race or ethnicity for at least one of the pathogens of interest.

Results: Fifty-four observational studies in 59 publications met our inclusion criteria. Studies reported results for Enterobacterales, *Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus*, and were conducted in Australia, Brazil, Israel, New Zealand, and USA. USA studies most often examined Black and Hispanic minority groups with studies regularly reporting a higher risk of these pathogens in Black persons and mixed results for Hispanic persons. Ethnic minority groups (e.g. Bedouins in Israel, Aboriginals in Australia) were often reported to be at a higher risk in other countries.

Conclusion: Sufficient evidence was identified in this scoping review justifying future systematic reviews and meta-analyses evaluating the relationship between community-acquired pathogens and race and ethnicity. However, we noted that only a fraction of studies reported data stratified by race and ethnicity, highlighting a substantial gap in the literature.

Key words: community-acquired, antimicrobial resistant, health disparities, race, ethnicity

RESEARCH IN CONTEXT

Evidence before this study

Racial and ethnic disparities in colonization and community-acquired infection with key bacterial pathogens have previously been reported, but global evidence has not been compiled to date. Literature was searched for in MEDLINE, Daily, Global Health, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Web of Science Core Collection from inception through January 2022, utilizing MeSH terminology and keywords for Community-Acquired Infections, Outpatients, Ambulatory Care, Socioeconomic Factors, Health Status Disparities, Healthcare Disparities, Continental Population Groups, Ethnic Groups, Gram-Negative Bacteria, and individual ESKAPE pathogens.

Added value of this study

To the best of our knowledge, this is the first compilation of global evidence for racial and ethnic disparities in colonization/infection with priority bacterial pathogens that are increasingly antimicrobial-resistant (AMR). While most studies we included were conducted in the USA, we also identified relevant studies from Brazil, Israel, Australia, and New Zealand. In general, persons belonging to racial or ethnic minority groups within these countries – especially Black persons in the USA and Brazil, Aboriginal persons in Australia and New Zealand, and Arabs or Bedouins persons in Israel - were at higher risk for colonization/infection with the pathogens of interest compared to majority groups, despite there being no biological basis for such differences. We identified several gaps that merit consideration in future studies, including incongruent classifications of race and ethnicity across studies, limited research among Indigenous and First Nations populations in the US, Canada, and Central and South America, and a lack of studies that reported colonization or infection rates stratified by individuals' race or ethnicity.

Implications of all the available evidence

Our findings indicate that global efforts to equitably prevent, diagnose, and treat bacterial infections that are increasingly AMR will be challenging unless strategies that account for racial and ethnic disparities are considered.

INTRODUCTION

Racial and ethnic disparities in communicable disease risk have widely been reported in the USA and other countries.[1,2] Recently, stark disparities in COVID-19 hospitalizations and deaths among racial and ethnic minority groups across several countries have drawn renewed attention to this challenge. Antimicrobial-resistant (AMR) bacterial infections are a developing threat to global public health.[3,4] AMR infections are often acquired outside of healthcare settings, *i.e.*, in the community, with individuals who are colonized or carrying these organisms in the gut, on the skin, in the nares, or on other mucosal surfaces often at higher risk for subsequent infection with the same organism.[5,6] Compared to infections with susceptible pathogens, infections with AMR pathogens lead to significantly longer hospital stays, increased healthcare-associated costs, and higher risks of death.[7] To date, it remains unclear whether specific racial or ethnic groups may be disproportionately at risk of colonization or infection with priority bacterial pathogens that are increasingly AMR, including *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter* species, and *Escherichia coli*. Knowing if certain groups are at disproportionately higher risk is essential for ensuring that AMR infections are equitably prevented, detected, and treated in the future.

There is no biological basis for racial or ethnic differences in rates of colonization or infection with priority bacterial pathogens; nevertheless, such differences may exist because race and ethnicity are closely intertwined with individuals' socioeconomic status (SES) and the social determinants of health (SDOH) more broadly, at least in part due to structural racism.[8] While using more specific indicators than race or ethnic status in clinical decision-making would be preferable to improve generalizability, variables related to the social determinants of health can be challenging to measure and have not traditionally been collected in many healthcare settings.[9] Thus, compiling global evidence for the association between an individual's racial or ethnic status and their risk of colonization or infection with priority bacterial pathogens is

valuable for summarizing current evidence, assessing gaps, and guiding more nuanced data collection in the future.

Scoping reviews are used to compile and descriptively summarize current published evidence on a scientific topic, as well as to identify gaps where additional research could be beneficial. Our specific objective in this scoping review was to compile and summarize existing evidence for an association between individuals' racial or ethnic background and their risk of colonization or infection with select community-acquired bacterial pathogens that are increasingly AMR.

METHODS

Objectives

The questions guiding this scoping review were: (1) What evidence exists for the association between an individual's racial or ethnic background and their risk of being colonized or infected with a community-acquired priority pathogen? and (2) What evidence exists for the association between an individual's socioeconomic status (SES) and their risk for these outcomes? Here we report the evidence identified for the association between race, ethnicity, and risk of colonization or infection with a community-acquired priority pathogen. Findings regarding the association between SES and community-acquired priority pathogens are reported elsewhere.[10]

Search strategy

A comprehensive scientific literature search of MEDLINE (Ovid), MEDLINE Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, and Daily (Ovid), Global Health (Ovid), Embase (Elsevier), Cochrane Database of Systematic Reviews (Wiley), Cochrane Central Register of Controlled Trials (Wiley), and Web of Science Core Collection was conducted for studies that reported race, ethnicity, and at least one of the pathogens of interest. Search strategies were designed as a joint effort between team members, experts, and a librarian

using a combination of controlled vocabulary and free-text keywords. All searches were based on an initial MEDLINE search and utilized MeSH terminology and related keywords for the following concepts: Community-Acquired Infections, Outpatients, Ambulatory Care, Socioeconomic Factors, Health Status Disparities, Healthcare Disparities, Continental Population Groups, Ethnic Groups, Gram-Negative Bacteria, and individual ESKAPE pathogens. The MEDLINE strategy (**Supplementary Table S1**) was translated to each of the listed databases by Reference Manager, and all databases were searched from inception through January 2022, except for MEDLINE Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily for which the search covered 2017 through 10 January 2021. References were collected and deduplicated using Endnote X9, prior to export to Covidence for screening and management.[11]

Eligibility Criteria

We included peer-reviewed publications of any study design, except case-control or case-series, that reported data on race or ethnicity for at least one of the following pathogens: *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter* spp., or *Escherichia coli*, or for Enterobacterales (formerly called Enterobacteriaceae), an order which comprises several of our species of interest, *including E. coli*, *K. pneumonie*, and *Enterobacter* spp. We did not limit our inclusion criteria by age, country, or publication language and we included both infection and colonization (**Supplementary Table S2**). We excluded studies that reported infections with mixed pathogens if less than 50% of the pathogens were of interest unless subgroup data were reported for at least one pathogen of interest. We only included studies that reported outpatient or community-based data or specified that the patient's pathogen of interest was community-acquired. Studies that did not report outpatient or community data and which defined community acquisition based only on phenotype (e.g., susceptibility to gentamicin for *S. aureu*s) or sequence type (e.g., USA300 for *S. aureu*s), were excluded. We also excluded

studies that reported hospital-acquired pathogens in the comparator group. In studies reporting on colonization, we excluded studies that compared persistent versus cleared colonization.

We note that definitions of race, ethnicity, and "minority" groups vary by country and their historical contexts. We used authors' classifications of race and ethnicity whenever possible; for example, we included Hispanic as a race when authors reported it as such, even though current USA guidelines categorize Hispanic/Latino as an ethnicity. In papers from Israel, we categorized Bedouins, non-Bedouin Arabs, and Jewish persons as ethnicities, even though Bedouins and Arabs are a tribal or religious minority rather than a true racial or ethnic minority, and Jewish persons are of multiple races. We included these Israeli studies because they intended to examine the effect of minority status on colonization/infection with the pathogens of interest. We did not use the terms "White", "Caucasian", or "European" interchangeably in our data extraction or synthesis; rather, we used terms used by each study's authors.

Study Selection, Data Extraction, and Synthesis

Titles and abstracts of citations identified from the literature searches were screened in duplicate in Covidence using the predefined inclusion/exclusion criteria created in conjunction between team members and experts (**Supplementary Table S2**).[11] Any conflicts were resolved during team meetings, and full-text articles for any abstracts that met the inclusion criteria were retrieved and independently screened by two team members. A customized extraction form was created in Covidence by experienced team members to capture all relevant study data, including study design features, study definition of community-acquired, study population characteristics including race, ethnicity, exposure and comparator, outcomes of interest, and directionality of results. All team members piloted the extraction form to refine and capture all pertinent data. After the initial training, each study was independently

extracted by two team members, and any discrepancies between the two were resolved by a third team member. We extracted all comparisons between races or ethnicities and outcomes reported in each paper regardless of whether the authors conducted a statistical test. Extracted data from all included studies are summarized across common parameters in narrative form, tables, and figures using R and Microsoft Excel 2021.

RESULTS

Our literature search identified 1039 citations that potentially reported data for race, ethnicity, or SES for patients colonized or infected with at least one of the pathogens of interest. Of these, 388 abstracts met the eligibility criteria and proceeded to full-text review (**Supplementary Figure S1**) of which 59 publications (**Supplementary Table S3**) were found to meet all inclusion criteria for race and ethnicity.[3,12–69] Four cohort studies were described in 2-3 separate publications each, meaning 54 distinct studies were identified in total.

Study characteristics

Among the 54 included studies,[3,12–69] 42 (78%) described infections and 12 (22%) described colonization with at least one of the pathogens of interest (**Table 1**).[13,18,26,33,37,43,45,47,50,51,53–55,57] Most studies were from the USA (n=42),[3,14–17,20,21,21,23–28,30–33,37,38,40–42,44–51,53–63,67–69] although studies from Israel (n=5),[13,29,34,36,39,52] New Zealand (n=4),[12,43,64–66] Australia (n=2),[19,35] and Brazil (n=1)[18] were also identified (**Figure 1**). Studies of infection most often included patients with skin and soft tissue infection (SSTI) caused by *S. aureus* or urinary tract infection (UTI) caused by *E. coli* or other Enterobacterales, while other infections like community-acquired pneumonia (CAP) were described more rarely. Study definitions of community-acquired infection included no hospitalization within the last 30 days or one year or samples collected either at admission or up to 72 hours after admission. For studies that reported on colonization, samples were typically collected from the skin or nares.

Race

Black vs. White persons

Thirty-two observational studies in 35 publications compared Black persons to White persons (**Table 2, Figure 2**).[14–18,22,22,24,26–28,30–33,37,38,40–42,44–48,51,53,58–60,62,67–69] Twenty-five observational studies in 26 publications reported on Methicillin-resistant Staphylococcus aureus (MRSA) or *S. aureus*,[14–17,21,24–28,30,32,33,37,38,41,44,46–48,53,56,57,60,62,67] four on *E. coli*,[22,58,59,68] one on Enterobacterales,[69] one on SSTI caused by varied pathogens,[22] and one on UTI caused by varied pathogens.[42] Most studies reported Black persons to be at higher risk of MRSA colonization or infection, at either a lower or equivalent risk of *S. aureus* colonization and infection, and at either a higher or no difference in risk for infection with other pathogens.

Fifteen studies reported that Black individuals were at a higher risk of MRSA infection or colonization than White individuals.[14,15,17,26,32,33,38,41,44,46,47,53,60,62,67] A multi-city prospective cohort study in the USA reported a higher risk of MRSA infection in Black to White persons in a southeastern urban center (Atlanta), but a lower risk in a mid-Atlantic city (Baltimore).[32] Black adult outpatients were reported to be at a higher risk of *S. aureus* SSTI that were non-susceptible to three or more antibiotic classes, i.e., multidrug-resistant (MDR) versus non-MDR *S. aureus* SSTI in one study, compared to participants who were neither Black nor Hispanic.[48] One study conducted in Brazil with a total of 300 participants reported a more than five times higher risk of MRSA colonization vs. no MRSA colonization among Black participants than those who were not part of the Black minority.[18] Five observational studies in six publications did not find a significant difference in MRSA infection or colonization between races,[16,21,27,28,37,47] and four did not statistically compare MRSA among races.[24,30,37,57]

Some studies also examined differences in MSSA or non-resistant *S. aureus* among races, with mixed results. Two studies reported no significant difference in infection between Black and White participants,[40,60] two reported no difference between Black persons and other races in

infection or colonization rates,[28,45] and one reported a lower risk of colonization in mixed-age Black participants compared to White participants.[37,47,51]

Ray 2013 also reported a lower risk of SSTI vs no SSTI in a mixed-age population of Black than the White population,[60] while Casey 2013 did not find a difference between Black and White patients with SSTI compared to matched controls.[21]

Enterobacterales infections in Black persons were examined in six studies. Among four studies reporting *E. coli* infections,[22,58,59,68] two reported no significant difference between Black and White participants,[58,59] and two did not investigate differences between races for extended-spectrum beta-lactamase (EBSL)-producing- vs non-ESBL-producing *E. coli* or MDR vs non-MDR *E. coli* infections.[22,68] One retrospective cohort study that included 40,137 participants found Black adults to be at a higher risk than White adults of carbapenem-resistant Enterobacterales (CRE) vs susceptible Enterobacterales infections,[69] while one study that reported on pregnant women with and without antepartum pyelonephritis caused by *E. coli* or *Enterobacter* spp. did not find a difference between races.[42]

Hispanic (reported as race) vs. White persons

Seventeen studies reported Hispanic as a racial group (**Table 3**), all of which were conducted in the US.[15,16,20,21,27,28,41,42,44,46,48,57,58,60,67–69] Conflicting patterns were reported regarding Hispanic persons' risk of MRSA or *S. aureus* colonization/infection in 12 studies, Enterobacterales in five, and SSTI and UTI each in one study.

Compared to non-Hispanic White persons, two studies[46,60] reported a higher risk of MRSA vs. MSSA infection among Hispanic patients and one reported a higher risk of MRSA colonization vs. no MRSA colonization among Hispanic adults.[57] Meanwhile, one study reported a lower risk of MRSA vs. MSSA,[44] four reported no difference between Hispanic and White persons for

MRSA vs. MSSA,[16,21,27,28] MRSA vs *S. aureus*, and MSSA vs no *S. aureus*, and four did not report an analysis comparing outcomes between Hispanic and White persons.[15,41,48,67]

Of the five studies that reported Enterobacterales infections in Hispanic patients,[20,42,58,68,69] one study reported a higher risk of trimethoprim-sulfamethoxazole-resistant (TMP/SMX) versus TMP/SMX-susceptible *E. coli* infections,[20] one reported no difference in ESBL-producing *E. coli* infections between races,[58] and one did not report results for a comparison.[68] Another study compared CRE vs carbapenem-susceptible Enterobacterales infection rates between multiple races but did not report results for a comparison between Hispanic vs White persons.[69] Pregnant women with and without antepartum pyelonephritis caused by *E. coli* or *Enterobacter* spp. were examined in one study,[42] but no difference between races was found.

One study reported on SSTI vs No SSTI. The authors found a lower risk of SSTI caused by S*. aureus*, *P. aeruginosa*, and *E. coli* in a mixed-aged population of Hispanic persons, compared to White persons.[60]

Asian vs. White persons

Asian persons were reported to either have a lower risk or no difference in risk compared to other races in five studies all of which were conducted in the USA.[16,28,41,54,60] Two studies reported a lower risk of MRSA vs. MSSA infection or colonization in pediatric and mixed-age Asian populations as compared to other races,[41,60] while three reported no significant difference between races for MRSA vs. MSSA infection or no *S. aureus* colonization.[16,28,54]

No difference was found between Asian and White persons in four studies that compared MSSA or *S. aureus* infection or colonization with no *S. aureus*.[28,43,54,60] Two of these studies also reported data for SSTI vs no SSTI with one reporting a higher risk in Asian patients compared to those of European descent,[43,60] while another found a mixed age group of Asian individuals to be at a lower risk of SSTI than White individuals.[60]

Three studies reported data for Asian patients with *E. coli* infection, with varied results.[22,58,59] Of these, one study of adult women with fluoroquinolone-susceptible *E. coli* UTIs reported a higher risk of infections expressing higher-level resistance to levofloxacin (MIC >0.12) among Asian than White women,[59] another study reported no difference between races, and a third (20) didn't evaluate the comparison.[58]

Aboriginal, Māori, Pacific Islander vs. White persons

Six cohorts in seven publications reported results from Australia and New Zealand, where Aboriginals, Māori, and Pacific Islanders are minority populations.[12,19,35,43,64–66] These minority groups were generally found to be at higher risk of MRSA and *S. aureus* colonization or infection, as well as SSTI.

Four of these studies described MRSA colonization and infection among these ethnic groups.[12,19,35,65] Two studies from Australia that included inpatients with either SSTI or pediatric thoracic emphysema reported that Aboriginal and Torres Strait Islander children, but not Pacific Islander children, had as much as a four times higher risk of MRSA than MSSA infection relative to Caucasian or not Aboriginal and Torres Strait Islander children.[19,35] From New Zealand, two studies reported that relative to persons identifying as Māori, Asian, or of European descent, Pacific Islander persons were at a higher risk of MRSA infection compared to either MSSA or no MRSA.[12,66] One of these studies also reported that Pacific Islander children were almost three times more likely to have MRSA infections than European children.[66]

Pacific Islanders and Māori inpatient children in New Zealand were also reported to be at a higher risk of *S. aureus* vs no *S. aureus* infection relative to children of European descent in two studies.[64,66] Hobbs 2018 did not find a difference in *S. aureus* vs. no *S. aureus* colonization between races but reported that Pacific Islander (RR: 1.44; 95% CI: 1.28, 1.62) and Māori persons (RR: 1.46; 95% CI: 1.30, 1.64) were at a higher risk of SSTI versus no SSTI.[43]

Other races

Conflicting results were reported in studies that aggregated non-White racial groups into a single category and which reported on other races. Two USA studies compared MRSA infection risks among White to all non-White patients, with one reporting higher risks for MRSA vs MSSA and MRSA vs no MSSA cases among non-White than White patients, while the other did not report a significant difference.[25,56] Non-White vs White persons were also compared for differences in risk of colonization/infection with MSSA or *S. aureus* versus no *S. aureus,* with two studies reporting a higher risk of infection or colonization in non-White persons,[25,55] while one did not find a significant difference.[56] One study reported a higher risk of *S. aureus* colonization in non-Hispanic White participants than in other races.[47]

Results were mixed for three USA studies [3,23,49] that reported MRSA infections among Native Hawaiian, Pacific Islander, or Samoan persons and for four USA studies [14,31,41,60] that included a small percentage of American Indian, Alaskan Native, or Eskimo persons, or a mix of these minorities.

Ethnicity

Hispanic vs non-Hispanic persons

Ten cohorts in twelve publications reported Hispanic as an ethnicity (**Table 4**).[14,17,22,24,25,30,37,40,47,51,61,63] MRSA or *S. aureus* was reported in eight studies with conflicting results, *E. coli* was reported in three with two reporting higher risk in Hispanic persons, *K. pneumoniae* was reported in one, *P. aeruginosa* in one, SSTI in one, and UTI in one.

Compared to Non-Hispanic White persons, one study [14] reported a higher risk of MRSA infection vs. controls (patients with an unintentional traumatic brain injury) among Hispanic children while another study [25] that compared Hispanic to non-Hispanic persons reported a higher risk of MSSA vs no MSSA infection in a mixed-aged population. Three studies [25,37,47,51] reported no significant difference between ethnicities with regards to risk of colonization or

infection with MRSA and *S. aureus*, while two observational studies [17,37] reported a lower risk of MRSA vs. MSSA [15,37,44] compared to non-Hispanics or non-Hispanic White persons. Three studies included Hispanic individuals but did not investigate this relationship.[24,30,61]

Three studies reported *E. coli* infections in Hispanic persons.[22,61,63] One pediatric study reported that Hispanic children were at a higher risk than non-Hispanic children for *E. coli* UTIs that were non-susceptible to first-generation cephalosporin antibiotics.[63] Another study [22] that reported on two adult cohorts recruited from an outpatient population found that Hispanic adults compared to non-Hispanic adults were at a higher risk of MDR vs non-MDR *E. coli* infections, while a third study [61] did not report on the comparison for Hispanic vs non-Hispanic White persons for infections caused by *E. coli* versus other pathogens.

One study that compared patients with and without SSTI reported a significantly lower risk of SSTI among non-English speaking Hispanic persons compared to non-Hispanic White persons.[40] No significant difference was found between English-speaking Hispanic persons compared to non-Hispanic White persons.

A retrospective cohort study with a total of 601 patients reported a higher number of CAP cases caused by *P. aeruginosa* vs other pathogens among non-Hispanic White (20%) than Hispanic adults (7%).[61] This same study reported no difference among CAP caused by *K. pneumoniae* vs other pathogens between Hispanic (4%) and non-Hispanic White (5%) adults.

Bedouin vs. Jewish persons

Bedouin persons were generally reported to have either a higher or similar risk of infection or colonization with the pathogens of interest, relative to Jewish persons in Israeli studies.[13,29,34,36,39,52] Two studies compared the ethnicity of children either colonized or infected with MRSA to those with either MSSA or no MRSA.[13,34] Both studies found that Arab or

Bedouin children, who are the ethnic minority in Israel, were at a significantly higher risk of MRSA compared to Jewish children.

Outpatient Bedouin children were reported to be at a significantly higher risk of quinolone-resistant vs susceptible UTI caused by *K. pneumoniae, P. aeruginosa,* or *E. coli* than Jewish children in one study.[36] Another study examined antibiotic susceptibility patterns among various pathogens (*K. pneumoniae*, *Enterobacter* spp., and *E. coli*) causing inpatient UTIs among children and reported a higher risk of resistance to some antibiotics (e.g., ampicillin, TMP/SMX, cephalosporins) among Bedouin versus Jewish children, but no significant difference for other antibiotics (e.g., nitrofurantoin, meropenem, amikacin).[39] Another study reported a higher risk of UTI caused by ESBL-producing vs non-ESBL-producing bacteria in Arab children than Jewish children.[52] In a prospective cohort study of 223 adults with UTIs caused by *E. coli*, *P. aeruginosa*, or *Enterococcus faecium*, no difference in antibiotic susceptibility patterns was observed between Bedouin versus non-Bedouins adults.[29]

Middle Eastern vs. non-Middle Eastern White persons

One USA study of 214 patients reported a higher risk for ESBL-producing *E. coli* UTIs among people of Middle Eastern descent compared to Caucasian persons of non-Middle Eastern descent.[68] One additional Australian study included a very small number of Middle Eastern patients but did not report results for a comparison.

DISCUSSION

This scoping review found global evidence for racial and ethnic disparities in colonization/infection with priority bacterial pathogens that are increasingly AMR. While most studies we included were conducted in the USA, we also included studies from other countries, *i.e.*, Brazil, Israel, Australia, and New Zealand. In general, persons belonging to racial or ethnic minority groups within these countries – especially Black persons in the USA and Brazil, Aboriginal persons in Australia and New Zealand, and Arabs or Bedouins persons in Israel -

were often at higher risk for colonization/infection with the pathogens of interest (especially MRSA) compared to majority groups, despite there being no biological basis for such differences. Our findings indicate that global efforts to equitably prevent, diagnose, and treat bacterial infections that are increasingly AMR will be challenging unless strategies that account for these disparities are considered.

Racial and ethnic disparities in colonization/infection risks are likely underpinned by the SDOH. In a scoping review that was conducted in parallel to this one, we identified several SES characteristics that were associated with higher risks for colonization/infection with the same organisms reported here, including low educational attainment, low income levels, lack of healthcare access, residential crowding, and high neighborhood-level deprivation.[10] It is more biologically plausible that some or all of these characteristics drive differences in colonization/infection rates among minority groups; however, they are closely intertwined with race and ethnicity due at least in part to structural racism. Our findings may help identify specific racial or ethnic groups that would especially benefit from targeted analysis of the SDOH that are underlying differences in their health outcomes, with the ultimate goal of improving patient health.

We identified several gaps that merit consideration in future studies on this topic. First, particularly in the USA, studies classified race and ethnicity differently which made it challenging to compare and collate study findings. Some studies assessed race or ethnicity using a one-question format, where participants were classified as White, Black, Hispanic, Asian or “Other”. Other studies used a two-question format in which participants were classified by race and additionally, their ethnicity was categorized as Hispanic or not Hispanic. Still others combined both approaches to categorize participants as non-Hispanic Whites, non-Hispanic Black, non-Hispanic Asian, Hispanic, and “Other.” While these classifications did not prevent us from extracting comparisons for the White majority versus minority groups for the

purposes of this scoping review, a more streamlined approach for reporting race and ethnicity would be useful; updated recommendations are currently being drafted by the USA government. We also note that studies rarely included whether participants' race and ethnicity were self-reported. Given well-known discrepancies between the race or ethnicity that an individual might identify with and what hospital staff note in the medical record, especially in the USA,[70] this information is critical for evaluating the validity of a study's findings. We suggest that this information is required by scientific journals when studies seek to report racial or ethnic differences in colonization/infection with bacterial pathogens.

Second, we noted very few studies that included Indigenous populations, outside of studies from Australia and New Zealand. Indigenous populations are often poorly represented in scientific research, which makes it challenging to design prevention and treatment strategies that are effective among these groups.[71] During our initial study screening phase, we noted several studies that described colonization/infection with the pathogens of interest exclusively among Indigenous populations. Because these studies did not include a comparator group (e.g., a non-Indigenous population), they did not meet our inclusion criteria for this scoping review and were excluded. Consistent findings from Australia and New Zealand that Aboriginal populations were at higher risk of *S. aureus* and MRSA infections strongly support the need for further research among Indigenous and First Nations populations in the USA, Canada, and Central and South America, where there are sizeable populations.

Third, while we identified numerous studies that could have met inclusion criteria, many were ultimately excluded because they did not report results stratified by race or ethnicity. Authors typically had enough information to be able to report this data, but did not, likely because patients' race/ethnicity was a covariate they controlled for but not an exposure of interest. In future publications, providing health outcomes stratified by race or ethnicity could help to more comprehensively identify disparities.

Lastly, some USA studies excluded non-English speakers. Doing so, unfortunately, can lead to bias against a population that, because of language barriers, could harbor distinct risks of infection/colonization with pathogens that are commonly AMR.[22] One study we included explicitly compared non-English speakers to other races or ethnicities with regards to SSTI risk and reported a lower risk of SSTI in the non-English speaking population.[40] This finding demonstrates that this demographic may have different risks and should be represented in studies when possible.

Future Directions and Conclusion

This scoping review, together with our concurrent review of the association between SES and colonization/infection with community-acquired pathogens, establishes the critical need to better delineate the underlying causes of disparities in colonization/infection with priority pathogens that are increasingly AMR. Only once these contributors are understood can we begin to effectively dismantle disparities through clinical and public health interventions. Such interventions might include improving access to hygiene, decreasing crowding of living spaces, increasing access to healthcare, and supporting health literacy.

ABBREVIATIONS

AMR	Antimicrobial resistance
ATSI	Aboriginal and Torres Strait Islander
CA	Community-acquired
CA-AMR	Community-acquired antimicrobial resistance
CAP	Community-acquired pneumonia
CRE	Carbapenem-resistant Enterobacterales
ESBL	Extended Spectrum Beta-Lactamase
ESKAPE	Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.
MDR	Multi-drug resistant
MIC	Minimum inhibitory concentration
MRSA	Methicillin-resistant Staphylococcus aureus
MSSA	Methicillin-Sensitive Staphylococcus aureus
P. aeruginosa	Pseudomonas aeruginosa
S. aureus	Staphylococcus aureus
SES	Socioeconomic Status
SSTI	Skin and soft tissue infections
USA	United States of America
UTI	Urinary Tract Infection

DECLARATIONS

Contributors: MLN, CWC, and SD conceptualized the study. MLN, NN, and SD acquired the funding. RM, SD, NN, and CWC performed the literature search. SAB, EEA, NN, CWC, S Balaji, LM, SAA, SD, and MLN reviewed titles and abstracts, reviewed full texts, designed the data extraction template, and extracted data. EEA and SB prepared the tables and figures. EEA, RM, and MLN wrote the first draft of the manuscript. All authors reviewed and approved the manuscript.

Declaration of interests: The authors declare that they have no competing interests.

Data sharing: Supplemental tables and figures.

Acknowledgements: Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funders had no role in study design; in the collection, analysis, or interpretation of data; on in writing the manuscript. Funders had no role in study design; in the collection, analysis, or interpretation of data; on in writing the manuscript. CWC was supported by an IDSA Foundation and HIV Medicine Association Grants for Emerging Research/Clinician Mentorship (G.E.R.M.) Program Award. The ARLG Publications Committee reviewed the manuscript prior to submission for publication.

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

REFERENCES

1 Einsiedel LJ, Fernandes LA, Woodman RJ. Racial disparities in infection-related mortality at Alice Springs Hospital, Central Australia, 2000--2005. *Med J Aust* 2008; **188**: 568–71.

2 Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in diagnoses of HIV/AIDS--33 states, 2001-2004. *MMWR Morb Mortal Wkly Rep* 2006; **55**: 121–5.

3 Centers for Disease Control and Prevention (CDC). Community-associated methicillin-resistant Staphylococcus aureus infections in Pacific Islanders--Hawaii, 2001-2003. *MMWR Morb Mortal Wkly Rep* 2004; **53**: 767–70.

4 World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Geneva, Switzerland: WHO, 2017 https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.

5 Freedberg DE, Zhou MJ, Cohen ME, *et al.* Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. *Intensive Care Med* 2018; **44**: 1203–11.

6 Huang SS, Septimus E, Kleinman K, *et al.* Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial. *Lancet* 2019; **393**: 1205–15.

7 Poudel AN, Zhu S, Cooper N, *et al.* The economic burden of antibiotic resistance: A systematic review and meta-analysis. *PLoS One* 2023; **18**: e0285170.

8 Williams DR, Priest N, Anderson NB. Understanding associations among race, socioeconomic status, and health: Patterns and prospects. *Health Psychol* 2016; **35**: 407–11.

9 Flanagin A, Frey T, Christiansen SL, AMA Manual of Style Committee. Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. *JAMA* 2021; **326**: 621–7.

10 Blackmon SA, Avendano EE, Nirmala N, *et al.* Socioeconomic status and the risk for colonization or infection with priority bacterial pathogens: a global evidence map. *In submission*.

11 Covidence systematic review software. Veritas Health Innovation. Melbourne, Australia. Available at www.covidence.org.

12 Abeysekera N, Wong S, Jackson B, Buchanan D, Heiss-Dunlop W, Mathy JA. Evolving Threat of Community Acquired Methicillin Resistant Staphylococcus aureus Upper Extremity Infections in the South Pacific: 2011-2015. *J Hand Surg Asian Pac Vol* 2019; **24**: 129–37.

13 Adler A, Givon-Lavi N, Moses AE, Block C, Dagan R. Carriage of community-associated methicillin-resistant Staphylococcus aureus in a cohort of infants in southern Israel: risk factors and molecular features. *J Clin Microbiol* 2010; **48**: 531–8.

14 Ali F, Immergluck LC, Leong T, *et al.* A Spatial Analysis of Health Disparities Associated with Antibiotic Resistant Infections in Children Living in Atlanta (2002-2010). *EGEMS (Wash DC)* 2019; **7**: 50.

15 Bar-Meir M, Tan TQ. Staphylococcus aureus skin and soft tissue infections: can we anticipate the culture result? *Clin Pediatr (Phila)* 2010; **49**: 432–8.

16 Berens P, Swaim L, Peterson B. Incidence of methicillin-resistant Staphylococcus aureus in postpartum breast abscesses. *Breastfeed Med* 2010; **5**: 113–5.

17 Beresin GA, Wright JM, Rice GE, Jagai JS. Swine exposure and methicillin-resistant Staphylococcus aureus infection among hospitalized patients with skin and soft tissue infections in Illinois: A ZIP code-level analysis. *Environ Res* 2017; **159**: 46–60.

18 Bes TM, Martins RR, Perdigão L, *et al.* Prevalence of methicillin-resistant Staphylococcus aureus colonization in individuals from the community in the city of Sao Paulo, Brazil. *Rev Inst Med Trop Sao Paulo* 2018; **60**: e58.

19 Britton PN, Andresen DN. Paediatric community-associated Staphylococcus aureus: a retrospective cohort study. *J Paediatr Child Health* 2013; **49**: 754–9.

20 Burman WJ, Breese PE, Murray BE, *et al.* Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates. *Am J Med* 2003; **115**: 358–64.

21 Casey JA, Cosgrove SE, Stewart WF, Pollak J, Schwartz BS. A population-based study of the epidemiology and clinical features of methicillin-resistant Staphylococcus aureus infection in Pennsylvania, 2001-2010. *Epidemiol Infect* 2013; **141**: 1166–79.

22 Casey JA, Rudolph KE, Robinson SC, *et al.* Sociodemographic Inequalities in Urinary Tract Infection in 2 Large California Health Systems. *Open Forum Infect Dis* 2021; **8**: ofab276.

23 Castrodale LJ, Beller M, Gessner BD. Over-representation of Samoan/Pacific Islanders among patients with methicillin-resistant Staphylococcus aureus (MRSA) infections at a large family practice clinic in Anchorage, Alaska, 1996-2000. *Alaska Med* 2004; **46**: 88–91.

24 Cohen AL, Shuler C, McAllister S, *et al.* Methamphetamine use and methicillin-resistant Staphylococcus aureus skin infections. *Emerg Infect Dis* 2007; **13**: 1707–13.

25 Como-Sabetti KJ, Harriman KH, Fridkin SK, Jawahir SL, Lynfield R. Risk factors for community-associated Staphylococcus aureus infections: results from parallel studies including methicillin-resistant and methicillin-sensitive S. aureus compared to uninfected controls. *Epidemiol Infect* 2011; **139**: 419–29.

26 Crum-Cianflone NF, Shadyab AH, Weintrob A, *et al.* Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV). *Medicine (Baltimore)* 2011; **90**: 379–89.

27 David MZ, Mennella C, Mansour M, Boyle-Vavra S, Daum RS. Predominance of methicillin-resistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: risk factors and recurrence rates. *J Clin Microbiol* 2008; **46**: 3222–7.

28 Duggal P, Naseri I, Sobol SE. The increased risk of community-acquired methicillin-resistant Staphylococcus aureus neck abscesses in young children. *Laryngoscope* 2011; **121**: 51–5.

29 Elnasasra A, Alnsasra H, Smolyakov R, Riesenberg K, Nesher L. Ethnic Diversity and Increasing Resistance Patterns of Hospitalized Community-Acquired Urinary Tract Infections in Southern Israel: A Prospective Study. *Isr Med Assoc J* 2017; **19**: 538–42.

30 Forcade NA, Parchman ML, Jorgensen JH, *et al.* Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) study. *J Am Board Fam Med* 2011; **24**: 543–50.

31 Frei CR, Makos BR, Daniels KR, Oramasionwu CU. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. *J Pediatr Surg* 2010; **45**: 1967–74.

32 Fridkin SK, Hageman JC, Morrison M, *et al.* Methicillin-resistant Staphylococcus aureus disease in three communities. *N Engl J Med* 2005; **352**: 1436–44.

33 Fritz SA, Hogan PG, Hayek G, *et al.* Staphylococcus aureus colonization in children with community-associated Staphylococcus aureus skin infections and their household contacts. *Arch Pediatr Adolesc Med* 2012; **166**: 551–7.

34 Galper E, Bdolah-Abram T, Megged O. Assessment of infections rate due to community-acquired Methicillin-resistant Staphylococcus aureus and evaluation of risk factors in the paediatric population. *Acta Paediatr* 2021; **110**: 1579–84.

35 Gautam A, Wiseman GG, Goodman ML, *et al.* Paediatric thoracic empyema in the tropical North Queensland region of Australia: Epidemiological trends over a decade. *J Paediatr Child Health* 2018; **54**: 735–40.

36 Gottesman B-S, Low M, Almog R, Chowers M. Quinolone Consumption by Mothers Increases Their Children's Risk of Acquiring Quinolone-Resistant Bacteriuria. *Clin Infect Dis* 2020; **71**: 532–8.

37 Graham PL, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. *Ann Intern Med* 2006; **144**: 318–25.

38 Gualandi N, Mu Y, Bamberg WM, *et al.* Racial Disparities in Invasive Methicillin-resistant Staphylococcus aureus Infections, 2005-2014. *Clin Infect Dis* 2018; **67**: 1175–81.

39 Hain G, Goldbart A, Sagi O, Ben-Shimol S. High Rates of Antibiotic Nonsusceptibility in Gram-negative Urinary Tract Infection in Children With Risk Factors Occurring in the Preceding Month: Considerations for Choosing Empiric Treatment. *Pediatr Infect Dis J* 2021; **40**: 639–44.

40 Hemmige V, Arias CA, Pasalar S, Giordano TP. Skin and Soft Tissue Infection in People Living With Human Immunodeficiency Virus in a Large, Urban, Public Healthcare System in Houston, Texas, 2009-2014. *Clin Infect Dis* 2020; **70**: 1985–92.

41 Hermos C, Shiau R, Hsiang M, Chambers H, Pan E. Epidemiology of community-associated methicillin-resistant Staphylococcus aureus in San Francisco children. *J Pediatr Infect Dis* 2015; **04**: 247–59.

42 Hill JB, Sheffield JS, McIntire DD, Wendel GD. Acute pyelonephritis in pregnancy. *Obstet Gynecol* 2005; **105**: 18–23.

43 Hobbs MR, Grant CC, Thomas MG, *et al.* Staphylococcus aureus colonisation and its relationship with skin and soft tissue infection in New Zealand children. *Eur J Clin Microbiol Infect Dis* 2018; **37**: 2001–10.

44 Hota B, Ellenbogen C, Hayden MK, Aroutcheva A, Rice TW, Weinstein RA. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? *Arch Intern Med* 2007; **167**: 1026–33.

45 Huppert JS, Bennett K, Kollar LM, Pattullo L, Mortensen JE. MRSA: rare in the vagina. *J Pediatr Adolesc Gynecol* 2011; **24**: 315–6.

46 Immergluck LC, Leong T, Malhotra K, *et al.* Geographic surveillance of community associated MRSA infections in children using electronic health record data. *BMC Infect Dis* 2019; **19**: 170.

47 Kuehnert MJ, Kruszon-Moran D, Hill HA, *et al.* Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. *J Infect Dis* 2006; **193**: 172–9.

48 Lee GC, Dallas SD, Wang Y, *et al.* Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization. *J Antimicrob Chemother* 2017; **72**: 2461–8.

49 Len KA, Bergert L, Patel S, Melish M, Kimata C, Erdem G. Community-acquired Staphylococcus aureus pneumonia among hospitalized children in Hawaii. *Pediatr Pulmonol* 2010; **45**: 898–905.

50 Lipsky BA, Pecoraro RE, Chen MS, Koepsell TD. Factors affecting staphylococcal colonization among NIDDM outpatients. *Diabetes Care* 1987; **10**: 483–6.

51 Mainous AG, Hueston WJ, Everett CJ, Diaz VA. Nasal carriage of Staphylococcus aureus and methicillin-resistant S aureus in the United States, 2001-2002. *Ann Fam Med* 2006; **4**: 132–7.

52 Megged O. Extended-spectrum β-lactamase-producing bacteria causing community-acquired urinary tract infections in children. *Pediatr Nephrol* 2014; **29**: 1583–7.

53 Milstone AM, Carroll KC, Ross T, Shangraw KA, Perl TM. Community-associated methicillin-resistant Staphylococcus aureus strains in pediatric intensive care unit. *Emerg Infect Dis* 2010; **16**: 647–55.

54 Morita JE, Fujioka RS, Tice AD, *et al.* Survey of methicillin-resistant Staphylococcus aureus (MRSA) carriage in healthy college students, Hawai'i. *Hawaii Med J* 2007; **66**: 213–5.

55 Mork RL, Hogan PG, Muenks CE, *et al.* Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study. *Lancet Infect Dis* 2020; **20**: 188–98.

56 Nerby JM, Gorwitz R, Lesher L, *et al.* Risk factors for household transmission of community-associated methicillin-resistant Staphylococcus aureus. *Pediatr Infect Dis J* 2011; **30**: 927–32.

57 Popovich KJ, Smith KY, Khawcharoenporn T, *et al.* Community-associated methicillin-resistant Staphylococcus aureus colonization in high-risk groups of HIV-infected patients. *Clin Infect Dis* 2012; **54**: 1296–303.

58 Raphael E, Glymour MM, Chambers HF. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. *Antimicrob Resist Infect Control* 2021; **10**: 118.

59 Rattanaumpawan P, Nachamkin I, Bilker WB, *et al.* Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study. *J Antimicrob Chemother* 2015; **70**: 1547–51.

60 Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. *BMC Infect Dis* 2013; **13**: 252.

61 Restrepo MI, Velez MI, Serna G, Anzueto A, Mortensen EM. Antimicrobial resistance in Hispanic patients hospitalized in San Antonio, TX with community-acquired pneumonia. *Hosp Pract (1995)* 2010; **38**: 108–13.

62 See I, Wesson P, Gualandi N, *et al.* Socioeconomic Factors Explain Racial Disparities in Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Disease Rates. *Clin Infect Dis* 2017; **64**: 597–604.

63 Stultz JS, Francis N, Ketron S, *et al.* Analysis of Community-Acquired Urinary Tract Infection Treatment in Pediatric Patients Requiring Hospitalization: Opportunity for Use of Narrower Spectrum Antibiotics. *J Pharm Technol* 2021; **37**: 79–88.

64 Vogel AM, Borland A, van der Werf B, *et al.* Community-acquired invasive Staphylococcus aureus: Uncovering disparities and the burden of disease in Auckland children. *J Paediatr Child Health* 2020; **56**: 244–51.

65 Williamson DA, Ritchie SR, Lennon D, *et al.* Increasing incidence and sociodemographic variation in community-onset Staphylococcus aureus skin and soft tissue infections in New Zealand children. *Pediatr Infect Dis J* 2013; **32**: 923–5.

66 Williamson DA, Ritchie SR, Roberts SA, *et al.* Clinical and molecular epidemiology of community-onset invasive Staphylococcus aureus infection in New Zealand children. *Epidemiol Infect* 2014; **142**: 1713–21.

67 Worley ML, Seif JM, Whigham AS, Mims JW, Shetty AK, Evans AK. Suppurative cervical lymphadenitis in infancy: microbiology and sociology. *Clin Pediatr (Phila)* 2015; **54**: 629–34.

68 Zhu FH, Rodado MP, Asmar BI, Salimnia H, Thomas R, Abdel-Haq N. Risk factors for community acquired urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing Escherichia coli in children: a case control study. *Infect Dis (Lond)* 2019; **51**: 802–9.

69 Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. *BMC Infect Dis* 2017; **17**: 279.

70 Magaña López M, Bevans M, Wehrlen L, Yang L, Wallen GR. Discrepancies in Race and Ethnicity Documentation: a Potential Barrier in Identifying Racial and Ethnic Disparities. *J Racial Ethn Health Disparities* 2016; **4**: 812–8.

71 Vigil D, Sinaii N, Karp B. American Indian and Alaska Native Enrollment in Clinical Studies in the National Institutes of Health's Intramural Research Program. *Ethics Hum Res* 2021; **43**: 2–9.

Tables

Table 1. Characteristics of all included studies.

	Total (%)
N studies	54 in 59 publications
Age group	
Pediatric only	22 (40.7%)
Adults only	17 (31.4%)
Mixed age groups	15 (27.8%)
N analyzed range	33- 1,904,807
Study duration	4 months- 9 years
% Male range (N=43)	5.4- 98.1%
Women only	4 (7.4%)
Study country	
Australia	2 (3.7%)
Brazil	1 (1.8%)
Israel	5 (9.3%)
New Zealand	4 (7.4%)
USA	42 (77.8%)
Outcome type	
Colonization	12 (22.2%)
Infection	42 (77.8%)
Recruitment setting	
Inpatient	21 (38.8%)
Outpatients	14 (25.9%)
Both Inpatients and Outpatients	13 (24.1%)
Community	5 (9.3%)
Jail	1 (1.9%)
Pathogen	
MRSA	37 (68.5%)
Other *Staphylococcus aureus*	19 (35.2%)
Enterococcus faecium	1 (1.9%)
Escherichia coli	8 (14.8%)
Pseudomonas aeruginosa	2 (3.7%)
Klebsiella pneumoniae	1 (1.9%)
Enterobacterales	1 (1.9%)
Funding type (N=59)	
Academia only	2 (3.3%)
Federal only	16 (27.1%)
Industry only	2 (3.3%)
Mixed	13 (22.0%)
None	9 (15.3%)
Not reported	17 (28.8%)

Note: MRSA=Methicillin-resistant *S. aureus.*

Table 2: Characteristics of studies that included Black persons.

	Total (%)
N studies	32 in 35 publications
Age group	
Pediatric only	10 (31.3%)
Adults only	13 (40.6%)
Mixed age groups	9 (28.1%)
N analyzed range	33- 1904807
Study duration	56 days- 11 years
% Male range (N=25)	12.5- 93%
Women only	4 (12.5%)
Study country	
Australia	0 (0%)
Brazil	1 (3.1%)
Israel	0 (0%)
New Zealand	0 (0%)
USA	31 (96.9%)
Outcome type	
Colonization	7 (21.9%)
Infection	25 (78.1%)
Recruitment setting	
Inpatient	11 (34.4%)
Outpatients	10 (31.3%)
Both Inpatients and Outpatients	9 (28.1%)
Community	1 (3.1%)
Jail	1 (3.1%)
Pathogen	
MRSA or *Staphylococcus aureus*	25 (78.1%)
Enterococcus faecium	0 (0%)
Escherichia coli	4 (12.5%)
Pseudomonas aeruginosa	0 (0%)
Klebsiella pneumoniae	0 (0%)
Enterobacterales	1 (3.1%)
SSTI	1 (3.1%)
UTI	1 (3.1%)
Funding type	
Academia only	1 (3.1%)
Federal only	9 (28.1%)
Industry only	2 (6.3%)
Mixed	9 (28.1%)
None	4 (12.5%)
Not reported	7 (21.9%)
Reported directionality of effect measure, compared to White majority	
Higher risk	18 (56.3%)
No significant difference	12 (37.5%)
Lower risk	3 (9.4%)

Note: MRSA=Methicillin-resistant *S. aureus*. UTI=Urinary tract infection; SSTI=skin and soft. tissue infection.

Table 3. Characteristics of studies that included Hispanic persons as a race

	Total (%)
N studies	17
Age group	
Pediatric only	6 (35.3%)
Adults only	7 (41.2%)
Mixed age groups	4 (23.5%)
N analyzed range	33- 376262
Study duration	6 months- 10 years
% Male range (N=14)	5.4- 80%
Women only	2 (11.8%)
Study country	
Australia	0 (0%)
Brazil	0 (0%)
Israel	0 (0%)
New Zealand	0 (0%)
USA	17 (100%)
Outcome type	
Colonization	1 (5.9%)
Infection	16 (94.1%)
Recruitment setting	
Inpatient	7 (41.2%)
Outpatients	3 (17.6%)
Both Inpatients and Outpatients	6 (35.3%)
Community	0 (0%)
Jail	1 (5.8%)
Pathogen	
MRSA or Other *Staphylococcus aureus*	12 (70%)
Enterococcus faecium	0 (0%)
Escherichia coli	3 (17.6%)
Pseudomonas aeruginosa	0 (0%)
Klebsiella pneumoniae	0 (0%)
Enterobacterales	1 (5.9%)
SSTI	1 (5.9%)
UTI	1 (5.9%)
Funding type	
Academia only	0 (0%)
Federal only	3 (17.6%)
Industry only	2 (11.7%)
Mixed	3 (17.6%)
None	4 (23.5%)
Not reported	5 (29.4%)
Reported directionality of effect measure, compared to White majority	
Higher risk	4 (23.5%)
No significant difference	5 (29.4%)
Lower risk	3 (17.6%)

Note: MRSA=Methicillin-resistant *S. aureus*. UTI=Urinary tract infection; SSTI=skin and soft. tissue infection.

Table 4: Characteristics of studies that included Hispanic persons as an ethnicity

	Total (%)
N studies	10 in 12 publications
Age group	
Pediatric only	2 (20%)
Adults only	4 (40%)
Mixed age groups	4 (40%)
N analyzed range	119- 1904807
Study duration	56 days 8 years
% Male range (N=9)	12.5- 78%
Women only	0 (0%)
Study country	
Australia	0 (0%)
Brazil	0 (0%)
Israel	0 (0%)
New Zealand	0 (0%)
USA	10 (100%)
Outcome type	
Colonization	1 (10%)
Infection	9 (90%)
Recruitment setting	
Inpatient	3 (30%)
Outpatients	4 (40%)
Both Inpatients and Outpatients	2 (20%)
Community	1 (10%)
Jail	0 (0%)
Pathogen	
MRSA or Other *Staphylococcus aureus*	8 (80%)
Enterococcus faecium	0 (0%)
Escherichia coli	3 (30%)
Pseudomonas aeruginosa	1 (10%)
Klebsiella pneumoniae	1 (10%)
Enterobacterales	0 (0%)
SSTI	1 (10%)
UTI	1 (10%)
Funding type	
Academia only	0 (0%)
Federal only	4 (40%)
Industry only	0 (0%)
Mixed	5 (50%)
None	0 (0%)
Not reported	2 (20%)
Reported directionality of effect measure, compared to White majority	5 (50%)
Higher risk	5 (50%)
No significant difference	2 (20%)
Lower risk	

Note: MRSA=Methicillin-resistant *S. aureus*. UTI=Urinary tract infection; SSTI=skin and soft. tissue infection.

Figures



Figure 1. Study location for 54 studies describing individuals' risk of colonization or infection with priority pathogens by their racial or ethnic identity.



Figure 2. Frequency of reports of 7 priority bacterial pathogens or associated infections by racial or ethnic minority groups vs majority group, among 54 studies included in this scoping review.
Note: MRSA=Methicillin-resistant *S. aureus*. UTI=Urinary tract infection; SSTI=skin and soft. tissue infection.